The miR-200 family has emerged recently as a noticeable marker for predicting cancer prognosis and tumor progression. We aimed to review the evidence of miR-200c-141 genomic cluster as prognostic biomarkers in cancers. The results suggested that high level of miR-200c had no significant impact on OS (HR = 1.14 [0.77–1.69],P=0.501) and DFS/PFS (HR = 0.72 [0.45–1.14],P=0.161). Stratified analyses revealed that high miR-200c expression was significantly related to poor OS in serum/plasma (HR = 2.12 [1.62–2.77],P=0.000) but not in tissues (HR = 0.89 [0.58–1.37],P=0.599). High miR-200c expression was significantly associated with favorable DFS/PFS in tissues (HR = 0.56 [0.43–0.73],P=0.000) but worse DFS/PFS in serum/plasma (HR = 1.90 [1.08–3.36],P=0.027). For miR-141, we found that high miR-141 expression predicted no significant impact on OS (HR = 1.18 [0.74–1.88],P=0.482) but poor DFS/PFS (HR = 1.11 [1.04–1.20],P=0.003). Similarly, subgroup analyses showed that high miR-141 expression predicted poor OS in serum/plasma (HR = 4.34 [2.30–8.21],P=0.000) but not in tissues (HR = 1.00 [0.92–1.09],P=0.093). High miR-141 expression was significantly associated with worse DFS/PFS in tissues (HR = 1.12 [1.04–1.20],P=0.002) but not in serum/plasma (HR = 0.90 [0.44–1.83],P=0.771). Our findings indicated that, compared to their tissue counterparts, the expression level of miR-200c and miR-141 in peripheral blood may be more effective for monitoring cancer prognosis. High miR-141 expression was better at predicting tumor progression than survival for malignant tumors.
Prognostic role of tripartite motif containing 24 in various human solid malignant neoplasms
